Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.

Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton KD, Martins R, Poirier JT, Rudin CM, Milletti F, Cheng WY, Mack F, MacPherson D.

Sci Signal. 2019 Feb 5;12(567). pii: eaau2922. doi: 10.1126/scisignal.aau2922.

PMID:
30723171
2.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
3.

Fracture load and survival of anatomically representative monolithic lithium disilicate crowns with reduced tooth preparation and ceramic thickness.

Nawafleh NA, Hatamleh MM, Öchsner A, Mack F.

J Adv Prosthodont. 2017 Dec;9(6):416-422. doi: 10.4047/jap.2017.9.6.416. Epub 2017 Dec 14.

4.

Calculation of Magnetic Shielding Constants with meta-GGA Functionals Employing the Multipole-Accelerated Resolution of the Identity: Implementation and Assessment of Accuracy and Efficiency.

Reiter K, Mack F, Weigend F.

J Chem Theory Comput. 2018 Jan 9;14(1):191-197. doi: 10.1021/acs.jctc.7b01115. Epub 2017 Dec 28.

PMID:
29232503
5.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

PMID:
29121274
6.

Calculation and experimental measurement of paramagnetic NMR parameters of phenolic oximate Cu(ii) complexes.

Dawson DM, Ke Z, Mack FM, Doyle RA, Bignami GPM, Smellie IA, Bühl M, Ashbrook SE.

Chem Commun (Camb). 2017 Sep 21;53(76):10512-10515. doi: 10.1039/c7cc05098d.

PMID:
28868550
7.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
8.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
9.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21.

PMID:
27100354
10.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schäfer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U.

Oncol Lett. 2016 Mar;11(3):2195-2198. Epub 2016 Feb 4.

11.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
12.

The Impact of Core/Veneer Thickness Ratio and Cyclic Loading on Fracture Resistance of Lithium Disilicate Crown.

Nawafleh N, Hatamleh MM, Öchsner A, Mack F.

J Prosthodont. 2018 Jan;27(1):75-82. doi: 10.1111/jopr.12473. Epub 2016 Mar 9. No abstract available.

PMID:
26965298
13.

Therapy of leptomeningeal metastasis in solid tumors.

Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M.

Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Review.

PMID:
26827696
14.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

15.

Lithium Disilicate Restorations Fatigue Testing Parameters: A Systematic Review.

Nawafleh N, Hatamleh M, Elshiyab S, Mack F.

J Prosthodont. 2016 Feb;25(2):116-26. doi: 10.1111/jopr.12376. Epub 2015 Oct 27. Review.

PMID:
26505638
16.

2,5-Dimethyl-celecoxib inhibits cell cycle progression and induces apoptosis in human leukemia cells.

Sobolewski C, Rhim J, Legrand N, Muller F, Cerella C, Mack F, Chateauvieux S, Kim JG, Yoon AY, Kim KW, Dicato M, Diederich M.

J Pharmacol Exp Ther. 2015 Nov;355(2):308-28. doi: 10.1124/jpet.115.225011. Epub 2015 Sep 1.

PMID:
26330537
17.

Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample.

Ford ME, Wei W, Moore LA, Burshell DR, Cannady K, Mack F, Ezerioha N, Ercole K, Garrett-Mayer E.

Springerplus. 2015 Aug 12;4:411. doi: 10.1186/s40064-015-1208-z. eCollection 2015.

18.

Dual induction of mitochondrial apoptosis and senescence in chronic myelogenous leukemia by myrtucommulone A.

Grandjenette C, Schnekenburger M, Morceau F, Mack F, Wiechmann K, Werz O, Dicato M, Diederich M.

Anticancer Agents Med Chem. 2015;15(3):363-73.

PMID:
25469628
19.

The next generation of antibody drug conjugates.

Mack F, Ritchie M, Sapra P.

Semin Oncol. 2014 Oct;41(5):637-52. doi: 10.1053/j.seminoncol.2014.08.001. Epub 2014 Aug 12. Review.

PMID:
25440608
20.

Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.

Mack F, Schäfer N, Kebir S, Stuplich M, Schaub C, Niessen M, Scheffler B, Herrlinger U, Glas M.

Oncology. 2014;86(5-6):369-72. doi: 10.1159/000360295. Epub 2014 Jun 18.

PMID:
24942787
21.

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.

Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.

PMID:
24008924
22.

Anticancer effect of altersolanol A, a metabolite produced by the endophytic fungus Stemphylium globuliferum, mediated by its pro-apoptotic and anti-invasive potential via the inhibition of NF-κB activity.

Teiten MH, Mack F, Debbab A, Aly AH, Dicato M, Proksch P, Diederich M.

Bioorg Med Chem. 2013 Jul 1;21(13):3850-8. doi: 10.1016/j.bmc.2013.04.024. Epub 2013 Apr 22.

PMID:
23664494
23.

Vemurafenib for leptomeningeal melanomatosis.

Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M.

J Clin Oncol. 2013 Apr 10;31(11):e173-4. doi: 10.1200/JCO.2012.46.5773. Epub 2013 Mar 4. No abstract available.

PMID:
23460716
24.

Accuracy and reliability of methods to measure marginal adaptation of crowns and FDPs: a literature review.

Nawafleh NA, Mack F, Evans J, Mackay J, Hatamleh MM.

J Prosthodont. 2013 Jul;22(5):419-28. doi: 10.1111/jopr.12006. Epub 2013 Jan 4. Review.

PMID:
23289599
25.

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy.

Kebir S, Kuchelmeister K, Niehusmann P, Nelles M, Kim Y, Thanendrarajan S, Schäfer N, Stuplich M, Mack F, Scheffler B, Urbach H, Glas M, Herrlinger U.

Exp Hematol Oncol. 2012 Dec 5;1(1):37. doi: 10.1186/2162-3619-1-37.

26.

Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib.

Maiani E, Di Bartolomeo C, Klinger FG, Cannata SM, Bernardini S, Chateauvieux S, Mack F, Mattei M, De Felici M, Diederich M, Cesareni G, Gonfloni S.

Nat Med. 2012 Aug;18(8):1172-4. doi: 10.1038/nm.2852. No abstract available.

PMID:
22869180
27.

ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis.

Kelkel M, Cerella C, Mack F, Schneider T, Jacob C, Schumacher M, Dicato M, Diederich M.

Carcinogenesis. 2012 Nov;33(11):2162-71. doi: 10.1093/carcin/bgs240. Epub 2012 Jul 20.

PMID:
22822094
28.

Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.

Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin J, Filss C, Langen KJ, Schäfer N, Mack F, Schüller H, Simon M, Glas M, Pietsch T, Urbach H, Herrlinger U.

J Clin Oncol. 2012 Jul 20;30(21):e180-3. doi: 10.1200/JCO.2011.40.9565. Epub 2012 Jun 11. No abstract available.

PMID:
22689800
29.

Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines.

Teiten MH, Gaigneaux A, Chateauvieux S, Billing AM, Planchon S, Fack F, Renaut J, Mack F, Muller CP, Dicato M, Diederich M.

OMICS. 2012 Jun;16(6):289-300. doi: 10.1089/omi.2011.0136. Epub 2012 Apr 4.

PMID:
22475723
30.

The interaction of PKN3 with RhoC promotes malignant growth.

Unsal-Kacmaz K, Ragunathan S, Rosfjord E, Dann S, Upeslacis E, Grillo M, Hernandez R, Mack F, Klippel A.

Mol Oncol. 2012 Jun;6(3):284-98. doi: 10.1016/j.molonc.2011.12.001. Epub 2011 Dec 28.

31.

Changes in condylar cartilage after anterior mandibular displacement in juvenile pigs.

Gredes T, Mack H, Spassov A, Kunert-Keil C, Steele M, Proff P, Mack F, Gedrange T.

Arch Oral Biol. 2012 Jun;57(6):594-8. doi: 10.1016/j.archoralbio.2011.09.017. Epub 2011 Oct 29.

PMID:
22041020
32.

Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.

Schäfer N, Tichy J, Thanendrarajan S, Kim Y, Stuplich M, Mack F, Rieger J, Simon M, Scheffler B, Boström J, Steinbach JP, Herrlinger U, Glas M.

Oncology. 2011;80(5-6):330-2. doi: 10.1159/000330358. Epub 2011 Jul 27.

PMID:
21791942
33.

Incorporation of osteoblasts (MG63) into 3D nanofibre matrices by simultaneous electrospinning and spraying in bone tissue engineering.

Paletta JR, Mack F, Schenderlein H, Theisen C, Schmitt J, Wendorff JH, Agarwal S, Fuchs-Winkelmann S, Schofer MD.

Eur Cell Mater. 2011 May 15;21:384-95.

34.

A novel post-and-core restoration system--results of three years of clinical application of the "Wuerzburg Post".

Rottner K, Boldt J, Proff P, Spassov A, Gredes T, Mack F, Richter EJ.

J Physiol Pharmacol. 2008 Nov;59 Suppl 5:105-15.

PMID:
19075331
35.

Adaptation of myosin heavy chain mRNA expression after implantation of poly(3)hydroxybutyrate scaffolds in rat m. latissimus dorsi.

Mack HB, Mai R, Lauer G, Mack F, Gedrange T, Franke R, Gredes T.

J Physiol Pharmacol. 2008 Nov;59 Suppl 5:95-103.

PMID:
19075330
36.

Evaluation of shape and size changes of bone and remodelled bone substitute after different fixation methods.

Gedrange T, Mai R, Mack F, Zietek M, Borsos G, Vegh A, Spassov A, Gredes T.

J Physiol Pharmacol. 2008 Nov;59 Suppl 5:87-94.

PMID:
19075329
37.

The factors associated with body mass index in adults from the study of health in Pomerania (SHIP-0), Germany.

Mack F, Abeygunawardhana N, Mundt T, Schwahn C, Proff P, Spassov A, Kocher T, Biffar R.

J Physiol Pharmacol. 2008 Nov;59 Suppl 5:5-16.

PMID:
19075320
38.
39.

Risk indicators for missing teeth in working-age Pomeranians--an evaluation of high-risk populations.

Mundt T, Schwahn C, Mack F, Polzer I, Samietz S, Kocher T, Biffar R.

J Public Health Dent. 2007 Fall;67(4):243-9.

PMID:
18087995
40.

Morphofunctional changes of orofacial muscles in patients with unilateral or bilateral cleft lip, alveolus and palate.

Proff P, Weingärtner J, Koppe T, Fanghänel J, Mack F, Gedrange T.

Ann Anat. 2007;189(2):203-7.

PMID:
17419554
41.

Partial- or full-mouth examination assessing the dental and prosthetic status among elderly individuals.

Mack F, Mundt T, Ellis J, Schwahn C, Bernhard O, Proff P, Gedrange T, Kocher T, Biffar R.

Eur J Prosthodont Restor Dent. 2006 Dec;14(4):158-62.

PMID:
17205950
42.

Prevalence of single-tooth gaps in a population-based study and the potential for dental implants--data from the Study of Health in Pomerania (SHIP-0).

Mack F, Samietz SA, Mundt T, Proff P, Gedrange T, Kocher T, Biffar R.

J Craniomaxillofac Surg. 2006 Sep;34 Suppl 2:82-5.

PMID:
17071398
43.

Comparison of craniofacial morphology in patients with unilateral cleft lip, alveolus and palate with and without secondary osteoplasty.

Gesch D, Kirbschus A, Mack F, Gedrange T.

J Craniomaxillofac Surg. 2006 Sep;34 Suppl 2:62-6.

PMID:
17071394
44.

Evaluation of patient satisfaction after therapy of unilateral clefts of lip, alveolus and palate.

Landsberger P, Proff P, Dietze S, Hoffmann A, Kaduk W, Meyer FU, Mack F.

J Craniomaxillofac Surg. 2006 Sep;34 Suppl 2:31-3.

PMID:
17071388
45.

Private practice results of screw-type tapered implants: survival and evaluation of risk factors.

Mundt T, Mack F, Schwahn C, Biffar R.

Int J Oral Maxillofac Implants. 2006 Jul-Aug;21(4):607-14.

PMID:
16955613
46.

Bone graft substitutes in periodontal and peri-implant bone regeneration.

Bayerlein T, Mundt T, Mack F, Bienengräber V, Proff P, Gedrange T.

Folia Morphol (Warsz). 2006 Feb;65(1):66-9.

PMID:
16783741
47.

The morphological and clinical relevance of mandibular and maxillary bone structures for implantation.

Fanghänel J, Proff P, Dietze S, Bayerlein T, Mack F, Gedrange T.

Folia Morphol (Warsz). 2006 Feb;65(1):49-53.

PMID:
16783736
48.

pVHL function is essential for endothelial extracellular matrix deposition.

Tang N, Mack F, Haase VH, Simon MC, Johnson RS.

Mol Cell Biol. 2006 Apr;26(7):2519-30.

49.

The influence of dynamic occlusal interferences on probing depth and attachment level: results of the Study of Health in Pomerania (SHIP).

Bernhardt O, Gesch D, Look JO, Hodges JS, Schwahn C, Mack F, Kocher T.

J Periodontol. 2006 Mar;77(3):506-16.

PMID:
16512766
50.

Epidemiological evaluation of the multifactorial aetiology of abfractions.

Bernhardt O, Gesch D, Schwahn C, Mack F, Meyer G, John U, Kocher T.

J Oral Rehabil. 2006 Jan;33(1):17-25.

PMID:
16409512

Supplemental Content

Support Center